Clinical Report: Achieving Long-Term Sustainability in Inflammatory Bowel Disease Management
Overview
The global prevalence of inflammatory bowel disease (IBD) is rising, increasing demands on healthcare systems and raising concerns about sustainability. This review highlights the need for balancing clinical effectiveness with financial, systemic, and environmental sustainability, emphasizing patient-centered care and innovative strategies to reduce environmental impact while maintaining high-quality outcomes.
Background
IBD, including Crohn’s disease and ulcerative colitis, is expanding beyond high-income countries into newly industrialized and low-resource regions, challenging healthcare infrastructure. Advances in therapies and treat-to-target approaches have improved outcomes but increased monitoring and treatment burdens. Healthcare itself contributes significantly to global carbon emissions, necessitating environmentally responsible care models. Addressing sustainability in IBD involves clinical, systemic, financial, and environmental dimensions to ensure equitable and durable patient care.
Data Highlights
Healthcare accounts for approximately 4.4% of global carbon emissions, ranking as the fifth-largest emitter worldwide. Clinical decisions and healthcare delivery models contribute to 80% of these emissions. Rising IBD prevalence and complexity increase healthcare utilization and associated environmental impacts. Resource constraints in low-income settings further complicate sustainable care delivery.
Key Findings
IBD care sustainability requires balancing clinical effectiveness with affordability, feasibility, and environmental responsibility.
Treat-to-target strategies improve patient outcomes but may increase treatment burden, costs, and environmental waste.
Environmental factors like climate change and pollution may influence IBD development and exacerbations, linking patient health with planetary health.
Decarbonizing clinical pathways and reducing single-use materials are ethical and practical necessities in IBD management.
Integrated, scalable care models and responsible adoption of biosimilars can enhance equity and sustainability.
Patient-centered approaches including therapeutic drug monitoring and de-implementation of low-value practices optimize resource use and outcomes.
Clinical Implications
Clinicians should adopt treat-to-target strategies judiciously, balancing benefits with potential increased burdens and environmental impacts. Incorporating validated biomarkers and imaging can optimize monitoring efficiency. Emphasizing care coordination and patient engagement supports sustainable long-term management. Healthcare systems must prioritize resource-efficient diagnostics and therapies, including biosimilars, to maintain equitable access while reducing carbon footprint.
Conclusion
Sustainable IBD care demands coordinated, evidence-based strategies that integrate clinical efficacy with financial, systemic, and environmental considerations. Such an approach supports durable patient outcomes and planetary health amid rising disease prevalence and healthcare pressures.
References
Global Burden and Sustainability in IBD Care, 2025 -- Achieving Long-Term Sustainability in the Management of Inflammatory Bowel Disease
